Selux Diagnostics, Inc.

Nicholas Phelan

Eric D Stern

Kelly Flentie

Phenotypic antimicrobial susceptibility testing (AST), the gold-standard diagnostic that indicates whether an antimicrobial will be clinically effective, often suffer the slowest times-to-result for the most resistant pathogens. Here we introduce novel assays to be performed in parallel with standard AST assays that enable rapid, same-shift reporting of AST results for a plurality of pathogens. The assays developed here are further capable of detecting resistance to carbapenems, the most powerful class of beta-lactams commonly used as 'last-resort' antimicrobials.

Growing community of inventors

Charlestown, MA, United States of America

Nicholas Phelan